Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2007-10-01 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: VESOUL (70000), Haute-Saone
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL PHARMACIE CHANTELAT ALEXANDRE is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in VESOUL (70000),
this company of category PME
shows in 2017 a revenue of 1.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE CHANTELAT ALEXANDRE (SIREN 502283377)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
1 393 982 €
Net income
28 119 €
17 044 €
24 253 €
25 388 €
68 687 €
66 209 €
79 445 €
87 012 €
85 045 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
100 782 €
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
6.1%
Revenue and income statement
In 2025, EURL PHARMACIE CHANTELAT ALEXANDRE generates positive net income of 28 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 85 k€ -> 28 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
28 119 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 5%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 91%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
4.635%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
90.512%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
6.188
3.726
12.943
10.353
9.481
18.545
23.168
7.608
4.635
Financial autonomy
89.532
90.813
85.642
87.475
85.904
79.699
76.915
88.616
90.512
Repayment capacity
1.208
None
None
None
None
None
None
None
None
Cash flow / Revenue
5.105%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
4.632025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Excellent
In 2025, the debt ratio of EURL PHARMACIE CHANTELAT ... (4.63) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
90.51%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent+15 pts over 3 years
In 2025, the financial autonomy of EURL PHARMACIE CHANTELAT ... (90.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 979.78. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
830.367
752.253
1297.065
1355.65
824.259
988.696
1081.479
1100.169
979.781
Interest coverage
0.03
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
979.782025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Excellent
In 2025, the liquidity ratio of EURL PHARMACIE CHANTELAT ... (979.78) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution EURL PHARMACIE CHANTELAT ALEXANDRE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
102 834 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
20
0
0
0
0
0
0
0
0
Customer payment term (days)
5
177
114
0
0
0
86
0
0
Supplier payment term (days)
9
407
232
0
0
0
275
0
0
Positioning of EURL PHARMACIE CHANTELAT ALEXANDRE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of EURL PHARMACIE CHANTELAT ALEXANDRE is estimated at
446 673 €
(range 303 114€ - 700 892€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
303k€446k€700k€
446 673 €Range: 303 114€ - 700 892€
NAF 5 année 2025
Valuation method used
Net Income Multiple
28 119 €
×
15.9x
=446 674 €
Range: 303 115€ - 700 892€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE CHANTELAT ALEXANDRE with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE CHANTELAT ALEXANDRE
What is the revenue of EURL PHARMACIE CHANTELAT ALEXANDRE ?
The revenue of EURL PHARMACIE CHANTELAT ALEXANDRE in 2017 is 1.4 M€.
Is EURL PHARMACIE CHANTELAT ALEXANDRE profitable?
Yes, EURL PHARMACIE CHANTELAT ALEXANDRE generated a net profit of 28 k€ in 2025.
Where is the headquarters of EURL PHARMACIE CHANTELAT ALEXANDRE ?
The headquarters of EURL PHARMACIE CHANTELAT ALEXANDRE is located in VESOUL (70000), in the department Haute-Saone.
Where to find the tax return of EURL PHARMACIE CHANTELAT ALEXANDRE ?
The tax return of EURL PHARMACIE CHANTELAT ALEXANDRE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE CHANTELAT ALEXANDRE operate?
EURL PHARMACIE CHANTELAT ALEXANDRE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart